A new clinical trial, CONSTAN-ARG, will test the effectiveness of the #RUTI® vaccine to shorten treatment in #TB patients. #Archivel Farma has designed and set up a phase IIb clinical study called CONSTAN-ARG to…
The clinical trial will be carried out at the Germans Trias i Pujol Hospital in Badalona (Can RUTI), and it will include 300 healthy health professionals in direct contact with…
On January 29, Archivel Farma, represented by its CEO, Olga Rúe, and Dr. Pere Joan Cardona, scientific advisor to the company, participated in the annual meeting of the Tuberculosis Vaccine…
Archivel Farma is one of the eight partners of STriTuVad consortium, whose overall goal is to demonstrate how advanced computer modelling and simulation can be used to reduce the costs…
Dr Pere-Joan Cardona, inventor of RUTI® vaccine and Scientific Advisor of Archivel Farma, and Olga Rué, company’s CEO, participated in the symposium organized by the TuBerculosis Vaccine Initiative (TBVI), on January…
Archivel Farma, owner of the vaccine, has started a Phase IIa clinical trial to assess the safety and immunogenicity of RUTI® in patients affected by multidrug-resistent tuberculosis (MDR-TB). Dr Pere-Joan…
The peer-reviewed journal Frontiers in Microbiology has just published an article by Dr. Pere-Joan Cardona, scientific advisor of Archivel Farma, which analyzes the current state of research on therapeutic vaccines against tuberculosis. “The…
The prestigious magazine Plos One has just published the article “Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent…